Updated on 2025/03/25

写真a

 
TANAHASHI Kana
 
Organization
Graduate School of Medicine Program in Integrated Medicine Biomedical Regulation Lecturer
Graduate School
Graduate School of Medicine
Undergraduate School
School of Medicine Department of Medicine
Title
Lecturer

Degree 1

  1. Ph. D. （ 2015.3   Nagoya University ） 

To the head of Degree.▲

Research Interests 4

  1. 先天性乏毛症

  2. 遺伝性皮膚疾患

  3. 角化症

  4. 皮膚科学

To the head of Research Interests.▲

Research Areas 1

  1. Life Science / Dermatology

To the head of Research Areas.▲

Research History 2

  1. Nagoya University   Department of Dermatology, Nagoya University Graduate School of Medicine   Lecturer

    2023.4

  2. Nagoya University   Nagoya University Hospital Dermatology   Assistant Professor

    2019.5 - 2023.3

To the head of Research History.▲

Professional Memberships 2

  1. 日本研究皮膚科学会

    2014

  2. 日本皮膚科学会

    2007

To the head of Professional Memberships.▲

Committee Memberships 1

  1. 日本研究皮膚科学会   評議員  

    2015   

    　 More details

    Committee type：Academic society

To the head of Committee Memberships.▲
 

Papers 44

  1. Cutaneous inflammation with upregulated interleukin-36γ and TNFα in a patient with loricrin keratoderma.

    Maki T, Murakami M, Takeichi T, Noda T, Tanahashi K, Mitsuma T, Muro Y, Akiyama M

    The Journal of dermatology     2025.3

    　More details

    Language：English  

    DOI： 10.1111/1346-8138.17708

    PubMed

  2. Protruding nodular fasciitis on the face

    Akanabe, H; Tanahashi, K; Mori, S; Murakami, Y; Motoi, T; Akiyama, M

    JOURNAL OF DERMATOLOGY     2024.12

    　More details

    Language：English   Publisher：Journal of Dermatology  

    DOI： 10.1111/1346-8138.17591

    Web of Science

    Scopus

    PubMed

  3. <i>Mycobacterium marinum</i> infection successfully treated with oral administration of minocycline and thermotherapy

    Morita, Y; Tanahashi, K; Terashima-Murase, C; Fukaura, R; Oka, K; Yagi, T; Miyamoto, Y; Ato, M; Ishii, N; Akiyama, M

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 86 ( 4 ) page： 699 - 702   2024.11

    　More details

    Language：English   Publisher：Nagoya Journal of Medical Science  

    We report a case of a woman presenting with an erythematous finger nodule, with a history of exposure to tropical fish. The erythematous nodules subsequently spread proximally from the finger. Initial treatment with oral amoxicillin-clavulanate was unsuccessful, and she developed a drug eruption. Treatment with oral minocycline and thermotherapy was initiated, as we suspected infection with Mycobacterium marinum (M. marinum) from her history and clinical features. A culture from a skin biopsy from the finger grew M. marinum, confirming the diagnosis. There is no established treatment regimen for skin infections caused by M. marinum. In this case, it took time for cultures to confirm the diagnosis of non-tuberculous mycobacterial infection. While it would be ideal to await culture results, we felt it was better for the patient to initiate treatment, and in M. marinum infections, minocycline is considered particularly effective. However, it was envisaged that this would result in a prolonged treatment course, leading to potential resistance. Thermotherapy was added in an attempt to shorten the treatment period. This regime was successful, and the patient has remained free of recurrence since. The early initiation of treatment for cutaneous non-tuberculous mycobacterial infection requires aggressive suspicion. Also, testing, including adequate sampling and culturing, is essential for an accurate diagnosis. Slow-growing mycobacteria may take several months to be definitively diagnosed, as they grow only under certain conditions. Therefore, thorough clinical history-taking and information sharing with the microbiology team are essential. Our case illustrates this, and we believe this has important educational value.

    DOI： 10.18999/nagjms.86.4.699

    Web of Science

    Scopus

    PubMed

  4. Treating epidermolytic ichthyosis and ichthyosis with confetti with epidermal autografts cultured from revertant skin. Reviewed International journal

    Kana Tanahashi, Michihiro Kono, Takenori Yoshikawa, Yuika Suzuki, Masukazu Inoie, Yachiyo Kuwatsuka, Fumie Kinoshita, Takuya Takeichi, Masashi Akiyama

    The British journal of dermatology   Vol. 191 ( 3 ) page： 397 - 404   2024.6

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: No efficient treatment has been established yet for epidermolytic ichthyosis (EI) caused by pathogenic variants in KRT1 or KRT10. Patients with ichthyosis with confetti (IWC) show multiple normal-appearing spots, caused by the revertant somatic recombination of pathogenic variants that occurs at each spot independently. Additionally, some patients with EI have large areas of normal skin due to revertant postzygotic mosaicism. OBJECTIVE: To assess the feasibility transplanting cultured epidermal autografts (CEAs) produced from revertant epidermal keratinocytes in patients with EI and IWC. METHODS: We performed a clinical trial of treatment with CEAs produced from each patient's own revertant epidermal keratinocytes as a proof-of-concept study. This is a single-arm, open (masking not used), uncontrolled, single-assignment, treatment purpose study. The primary outcome was the rate of areas without the recurrence of ichthyosis lesions 4 weeks after the final transplant (%). The secondary outcome was the rate of areas without the recurrence of ichthyosis lesions 24 weeks after initial transplantation (%). RESULTS: We successfully produced CEAs from the genetically confirmed revertant skin of the two mosaic EI patients and one IWC patient and genetically confirmed that CEAs mainly consist of revertant wild-type cells by amplicon sequencing and droplet digital PCR analysis. Single-cell RNA sequencing analysis confirmed the normal proliferation and safety profiling of CEAs. CEAs were transplanted to desquamated lesional sites of the patients. Four weeks after this transplantation, the rate of areas without the recurrence of ichthyosis lesions in the three cases was 39.52%, 100.0%, and 100.0% respectively, although the recurrence of ichthyosis lesions was seen at the site of CEA transplantation in all three patients at 24 weeks after transplantation. CONCLUSION: CEAs from normal skin have the potential to be a safe and local treatment option for EI and IWC. TRIAL REGISTRATION: jRCTb041190097.

    DOI： 10.1093/bjd/ljae193

    Web of Science

    Scopus

    PubMed

  5. Cross-sectional nationwide epidemiologic survey on quality of life and treatment efficacy in Japanese patients with congenital ichthyoses. Reviewed International journal

    Yuika Suzuki, Kana Tanahashi, Chiaki Terashima-Murase, Takuya Takeichi, Yumiko Kobayashi, Fumie Kinoshita, Masashi Akiyama

    Journal of dermatological science   Vol. 113 ( 1 ) page： 2 - 9   2024.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Congenital ichthyoses sometimes present with severe skin symptoms that significantly affect the patient's quality of life (QOL). Symptomatic treatments are the mainstay therapies, and their efficacy is limited and inadequate. OBJECTIVE: To assess the disease severity and QOL in patients with congenital ichthyoses, and to investigate the effectiveness of current treatments. METHODS: We conducted a questionnaire-based Japan-wide epidemiological survey of patients with congenital ichthyosis who received medical care from 1 January 2016-31 December 2020. Effectiveness of past and current treatments was assessed. The outcomes were the physician's assessment, disease severity assessed using the clinical ichthyosis score (CIS), and the disease burden estimated using the Dermatology Life Quality Index (DLQI), the Children's Dermatology Life Quality Index (CDLQI), and the Infants' Dermatitis Quality of Life Index. RESULTS: One hundred patients with 14 ichthyosis subtypes from 47 institutes were included in the final analysis. The CDLQI score showed a positive correlation with CIS (rs = 0.59, p = 0.004), while the DLQI score showed no significant correlation (rs = 0.13, p = 0.33). All existing medications were effective for many patients. Etretinate improved QOL and reduced CIS, but side effects including bone growth retardation were reported. Decreased treatment willingness was observed in patients with very low and very high CIS. CONCLUSION: QOL scores were found to correlate with CIS in children, but not in adults. Considering the adverse events, it is speculated that etretinate is not indicated for children with mild cases. Petrolatum was the most commonly used medication, even in patients who were reluctant to receive treatment.

    DOI： 10.1016/j.jdermsci.2023.11.002

    Scopus

    PubMed

▼display all

To the head of Papers.▲

MISC 36

  1. 悪性黒色腫が多発したKRT10変異によるichthyosis with confettiの1例

    勅使河原 眞子, 武市 拓也, 棚橋 華奈, 室 慶直, 秋山 真志, 伊藤 靖敏, 中川 浩一, 萩 朋男

    角化症研究会記録集   Vol. 38   page： 17 - 20   2024.7

    　More details

    Language：Japanese   Publisher：角化症研究会事務局  

  2. BP180,BP230,ラミニンγ1,VII型コラーゲンに対する血清IgG自己抗体陽性の類天疱瘡の1例

    神谷 怜志, 棚橋 華奈, 鶴田 京子, 古賀 浩嗣, 石井 文人, 秋山 真志

    日本皮膚科学会雑誌   Vol. 134 ( 5 ) page： 1528 - 1528   2024.5

    　More details

    Language：Japanese   Publisher：(公社)日本皮膚科学会  

  3. 右示指に紅色結節を生じたMycobacterium marinum感染症の1例

    守田 佑香, 棚橋 華奈, 村瀬 千晶, 秋山 真志, 岡 圭輔, 宮本 友司, 阿戸 学

    日本皮膚科学会雑誌   Vol. 134 ( 4 ) page： 793 - 793   2024.4

    　More details

    Language：Japanese   Publisher：(公社)日本皮膚科学会  

  4. 丹毒様の臨床像を呈したfolliculotropic mycosis fungoidesの1例

    松田 真佑香, 棚橋 華奈, 秋山 真志

    日本皮膚科学会雑誌   Vol. 134 ( 4 ) page： 798 - 798   2024.4

    　More details

    Language：Japanese   Publisher：(公社)日本皮膚科学会  

  5. 動眼神経麻痺を伴った右三叉神経第一枝帯状疱疹の1例

    宿院 梨衣, 棚橋 華奈, 滝 奉樹, 秋山 真志, 野田 達宏, 滝 陽輔, 玉腰 大悟, 村上 あゆ香, 勝野 雅央

    日本皮膚科学会雑誌   Vol. 134 ( 4 ) page： 806 - 806   2024.4

    　More details

    Language：Japanese   Publisher：(公社)日本皮膚科学会  

▼display all

To the head of MISC.▲

Research Project for Joint Research, Competitive Funding, etc. 6

  1. 常染色体劣性先天性魚鱗癬における表皮脂質異常と分化異常のメカニズムの解明

    Grant number：2 0 K 1 7 3 4 8  2020.4

    日本学術振興会  科学研究費助成事業　若手研究 

    　 More details

    Authorship：Principal investigator  Grant type：Competitive

    Grant amount：\4160000 （ Direct Cost: \3200000 、 Indirect Cost：\960000 ）

  2. 先天性魚鱗癬における表皮脂質異常と表皮細胞分化障害のクロストークの解明

    2020.4 - 2021.3

    2020年度日比野基金医学研究助成 

    　 More details

    Authorship：Principal investigator  Grant type：Competitive

    Grant amount：\500000

  3. 表皮脂質関連遺伝子の異常による先天性魚鱗癬の病態解明と新規治療法の開発

    2019.4 - 2020.3

    2019年度基礎医学研究費（資生堂寄付） 

    　 More details

    Authorship：Principal investigator  Grant type：Competitive

    Grant amount：\1000000

  4. 次世代シークエンサーを用いた常染色体劣性先天性魚鱗癬の新規病因遺伝子の検索と包括的病態解明および新規治療法の研究

    2018 - 2019

    平成30年度医学研究奨励助成事業（臨床枠） 

    　 More details

    Authorship：Principal investigator  Grant type：Competitive

    Grant amount：\2000000

  5. アトピー性皮膚炎患者の皮膚バリア機能に関与する新規病因遺伝子の検索

    2017.11 - 2019.3

    GlaxoSmithKline Research Grant 2017 

    　 More details

    Grant type：Competitive

    Grant amount：\2000000

▼display all

To the head of Research Project for Joint Research, Competitive Funding, etc..▲

KAKENHI (Grants-in-Aid for Scientific Research) 4

  1. 先天性魚鱗癬の病態におけるリゾリン脂質の役割解明と新規治療標的への展開

    Grant number：22K16260  2022.4 - 2024.3

    科学研究費助成事業  若手研究

    棚橋 華奈

    　 More details

    Authorship：Principal investigator 

    Grant amount：\4550000 （ Direct Cost: \3500000 、 Indirect Cost：\1050000 ）

    本研究は、常染色体劣性先天性魚鱗癬（autosomal recessive congenital ichthyosis: ARCI）の包括的病態解明と新規治療法開発に直結する基礎的データを得ることを目的とする。具体的には、ARCI表皮モデル及びモデルマウスについて、表皮分化、リゾリン脂質などの脂質メディエーター、サイトカインに関連する遺伝子発現の変化を分析することで、表皮脂質異常が表皮の分化・増殖に影響をもたらすメカニズムを解明する。

  2. Elucidation of crosstalk between epidermal lipid abnormality/barrier defects and inflammation in ichthyosis for innovation of novel treatments

    Grant number：21H02941  2021.4 - 2024.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    　 More details

    Authorship：Coinvestigator(s) 

  3. 表皮脂質異常・バリア障害・炎症、三位一体の魚鱗癬発症機序解明と現実的治療法の開拓

    Grant number：24K02470  2024.4 - 2027.3

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    秋山 真志, 室 慶直, 棚橋 華奈, 滝 奉樹, 桃原 真理子

    　 More details

    Authorship：Coinvestigator(s) 

    本研究では、多数の常染色体劣性先天性魚鱗癬(ARCI)患者と多系統の遺伝子改変魚鱗癬モデルマウス、皮膚炎症誘発マウスを対象に、表皮機能脂質の分析、角層バリア機能の評価、皮膚・血液でのシングルセル解析を含めた遺伝子発現プロファイリングを行う。そのデータから、表皮脂質異常、バリア障害、炎症の鍵となる分子、経路を明らかにする。さらに、表皮脂質異常・角層バリア障害・皮膚炎症の三位一体の病態の核となる分子、経路を特定し、それらを標的としたモデルマウス植皮治療実験により、ARCIの新規治療法を提案する。この新規治療法には、皮膚脂質異常、バリア障害を病因とする炎症性疾患の治療、予防への波及効果が期待される。

  4. 常染色体劣性先天性魚鱗癬における表皮脂質異常と分化異常のメカニズムの解明

    Grant number：20K17348  2020.4 - 2022.3

    若手研究

    棚橋 華奈

    　 More details

    Authorship：Principal investigator 

    Grant amount：\4160000 （ Direct Cost: \3200000 、 Indirect Cost：\960000 ）

    本研究は、最重症の魚鱗癬である道化師様魚鱗癬を含む常染色体劣性先天性魚鱗癬（autosomal recessive congenital ichthyosis: ARCI）の包括的病態解明と新規治療法開発に直結する基礎的データを得ることを目的とする。具体的には、胎生期から成体まで観察が可能なARCIモデルマウスを樹立し、表皮分化、脂質代謝、サイトカインなどの変化を分析することで、表皮脂質異常が表皮の分化・増殖に影響をもたらすメカニズムを解明し、魚鱗癬治療候補薬を見つけ出す。本研究の成果は皮膚バリア障害を発症因子とするアレルギー性疾患の予防、治療へと波及することが期待される。

To the head of KAKENHI (Grants-in-Aid for Scientific Research).▲